Shenyang Rongke Rongtuo Health Data Industry Equity Investment Partnership (Limited Partnership) signed share acquisition agreement to acquire 63% stake in Demei Zhenlian Medical Treatment Investment Management Co., Ltd from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (SEHK:1349), Zhonghe Houde Investment Management Co., Ltd, Beijing Fengyuan Tianxiang Medical Treatment Investment Management Co., Ltd, Tengzheng Business Management Consulting (Suzhou) Co., Ltd and Shanghai Zengxiang Investment Co., Ltd for CNY 34.7 million on February 28, 2019. Under the terms, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical will sell 30.04% stake for CNY 16.5 million, Zhonghe Houde Investment Management will sell 5% stake for CNY 2.8 million, Beijing Fengyuan Tianxiang Medical Treatment Investment Management will sell 7.96% stake for CNY 4.4 million, Tengzheng Business Management Consulting (Suzhou) Co., Ltd will sell 10% stake for CNY 5.5 million and Shanghai Zengxiang Investment Co., Ltd will sell 10% stake for CNY 5.5 million. Post-acquisition, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd, Zhonghe Houde Investment Management Co., Ltd and Beijing Fengyuan Tianxiang Medical Treatment Investment Management Co., Ltd wil hold 20% stake, 10% stake and 7% stake respectively in Demei Zhenlian Medical Treatment Investment Management. The transaction does not need the approval of the Bringspring Science and Technology’s directorate Shenyang Rongke Rongtuo Health Data Industry Equity Investment Partnership (Limited Partnership) cancelled the acquisition of 63% stake in Demei Zhenlian Medical Treatment Investment Management Co., Ltd from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (SEHK:1349), Zhonghe Houde Investment Management Co., Ltd, Beijing Fengyuan Tianxiang Medical Treatment Investment Management Co., Ltd, Tengzheng Business Management Consulting (Suzhou) Co., Ltd and Shanghai Zengxiang Investment Co., Ltd on February 28, 2020.